Navigation Links
Lilly Stops Phase III Development of Pomaglumetad Methionil For the Treatment of Schizophrenia Based on Efficacy Results
Date:8/29/2012

INDIANAPOLIS, Aug. 29, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today the decision to stop ongoing clinical studies investigating pomaglumetad methionil, also known as mGlu2/3, for the treatment of patients suffering from schizophrenia. The decision was made after a recently conducted independent futility analysis concluded HBBN, the second of Lilly's two pivotal studies, was unlikely to be positive in its primary efficacy endpoint if enrolled to completion. The decision was not based on any safety signals.

Additionally, the recently completed Phase II study, HBCO, which investigated pomaglumetad methionil as an adjunctive treatment with atypical antipsychotics, did not meet its primary endpoint. 

Lilly is contacting study investigators to outline specific actions related to the close-out of each ongoing study. Lilly will work with study investigators to ensure an appropriate transition of study participants to continuing clinical care outside of the trials.

"I'm disappointed in what these results mean for patients with schizophrenia who still are searching for options to treat this terrible illness," said Jan Lundberg, Ph.D., executive vice president, science and technology, and president, Lilly Research Laboratories.  "While there are many challenges in this complex field of research, neuroscience remains a core area of focus at Lilly. Our clinical development pipeline includes nearly a dozen neuroscience molecules being studied to treat illnesses such as depression, bipolar disorder and cognitive impairment associated with schizophrenia."

The decision to stop ongoing Phase III development of pomaglumetad methionil is expected to result in a third-quarter charge to R&D expense in the range of $25 million to $30 million (pre-tax), or approximately $0.02 per share (after-tax).  The company's previously-iss
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. U.S. Court of Appeals Upholds Validity of Lillys Alimta Compound Patent
2. Lilly Revises 2012 Reported Guidance to Reflect Income from Early Payment of Amylin Obligations
3. Lilly Announces Study Results Regarding Postmenopausal Women with Back Pain Caused by Vertebral Fractures
4. Lilly Supports Research to Determine What a Dogs Nose Knows About People with Diabetes and Severe Hypoglycemia
5. Lilly Reports Second-Quarter 2012 Results, Raises 2012 EPS Guidance
6. Lilly Confirms Date and Conference Call for Second-Quarter 2012 Financial Results Announcement
7. Lilly Announces Pomaglumetad Methionil Did Not Meet Primary Endpoint of Clinical Study
8. Lilly Diabetes Announces Once Upon A Time Contest Winner
9. Lilly Statement on Affordable Care Act Ruling by Supreme Court
10. Lilly Statement on PDUFA Vote by Senate
11. PrimeraDx Announces Commencement of Product Development Collaboration with Eli Lilly and Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Switzerland , September ... receiving ISO 13485 accreditation, Sophia Genetics has become the ... clinical use of a Next Generation Sequencing (NGS) ... certification represents an important step in raising the ... and brings Sophia Genetics, world-leading Data Driven Medicine ...
(Date:9/2/2014)... Calif. , Sept. 2, 2014 Redspin, ... and penetration testing services, today released an IT security ... "Today,s healthcare CEOs are presiding over the ... said Daniel W. Berger , Redspin,s President and ... CEO,s and their Boards of Directors understand why they ...
(Date:9/2/2014)... , September 2, 2014 ... Drugs Market - Global Industry Analysis, Size, Share, ... to grow at a CAGR of 10.1% from 2014 ... from living cells and are used in the treatment ... diseases, auto-immune diseases and other medical disorders. Biological drugs ...
Breaking Medicine Technology:Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 2CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 3CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 4CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 5CAGR of 10.1% Global Biological Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 to 2020: Report by MarketResearchReports.Biz 6
... Data presented today,at the Annual Congress of ... oral Factor Xa inhibitor DU-176b reduced the incidence,of ... elective unilateral hip replacement surgery. There was a,statistically ... the,observed bleeding rates were low across the groups. ...
... Bypass Surgery for Safety and ... Condition, WASHINGTON, Sept. 1 Patients with both ... will find good news in,new findings announced today from ... Interventions (SCAI). The one-year findings,of the new study indicate ...
Cached Medicine Technology:Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b 2SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI 2SCAI: CARDia Data Find Diabetic Patients With Complex Heart Disease Can Safely Choose PCI 3
(Date:9/2/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief executive officer ... Sioux Falls, S.D. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... and nationally recognized leader in patient-centered care. It is ...
(Date:9/2/2014)... With thoughts of getting the kids ready to ... Washingtonians, it’s easy to forget that this is prime ... be booking their organizations’ holiday parties throughout the Washington, ... locations are preparing for the holiday rush. , “While ... the space appears to be going faster this year,” ...
(Date:9/2/2014)... At the world-famous Magic Castle in Hollywood, California, famed ... being the first and only female staff Medium. Throughout the ... female magician to hold such a position. , “I’m deeply ... says Misty Lee. “Even since I was a child, magic ... can fascinate guests in much the same way.” , At ...
(Date:9/2/2014)... 02, 2014 “Is there an ultimate ... that millions of people ask. Diagnosing and curing scabies ... and their families or treatment partners. The diagnostic challenge ... distinct similarities to other skin conditions such as: papular ... eczema, varicella and many others. Scabies is also ...
(Date:9/2/2014)... 02, 2014 On August 22 and ... Associates in Duluth, GA and Precious Hearing Inc. in ... team at the 2014 National Basketball Retired Players Association ... While interacting with the former players and their families ... team provided free hearing screenings, video ear inspections, and ...
Breaking Medicine News(10 mins):Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 3Health News:Fall in Washington, DC, Is When a Meeting Planner’s Mind Turns to … the Winter Holidays? 2Health News:Fall in Washington, DC, Is When a Meeting Planner’s Mind Turns to … the Winter Holidays? 3Health News:Fall in Washington, DC, Is When a Meeting Planner’s Mind Turns to … the Winter Holidays? 4Health News:Fall in Washington, DC, Is When a Meeting Planner’s Mind Turns to … the Winter Holidays? 5Health News:Magician Misty Lee is the First and Only Female Staff Medium at Hollywood’s Magic Castle 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:The EarQ Team Brings Hearing Health Awareness to the 2014 National Basketball Retired Players Association Annual Convention in Cancun 2
... population increases, so does its need for long-term care. And ... they need particularly in the area of pay and ... Research on the Long-Term Care Workforce," the latest special ... Special Issue 1). , Those aged 65 and older are ...
... to settle question about best treatment for the disease ... update from a European study that has followed men ... the debate about the advantages of aggressive treatment versus ... for men who underwent surgery to remove the prostate ...
... today launched an online campaign (http://www.votekids08.org ) ... the importance of investing in the,key building blocks ... issues must be a priority for all Presidential ... have,adequate health care, quality early care and education, ...
... 12 Online Internet,shopping today offers many benefits. You ... home and purchase most anything by clicking a mouse.,But ... the Internet,bypassing a traditional office visit or conversation with ... researchers from Utah and,several colleagues compare the relative safety ...
... Esoteric,Laboratory Institute Main Laboratory, Van Nuys, California, has ... Accreditation of,the College of American Pathologists (CAP), based ... PathNet,s Laboratory Director, Juan Felix, MD, was advised ... of the services,being provided." PathNet Esoteric Lab Institute ...
... cancer onto a sucker punch by getting infected cells to ... are using the metal ruthenium as a catalyst to a ... oxidants as an ally. , Cancer adapts quickly to ... laboratory tests reveal a second line of defence using ruthenium ...
Cached Medicine News:Health News:Long-term care workers struggle with elderly population boom 2Health News:Surgery Helps With Prostate Cancer, Sometimes 2Health News:Surgery Helps With Prostate Cancer, Sometimes 3Health News:VOICES Launches 'Vote Kids 2008' to Engage Voters and Candidates in Shaping National Policies for America's Children 2Health News:Researchers Examine Safety of Internet Prescriber Service Providing Erectile Dysfunction Medications 2Health News:Researchers Examine Safety of Internet Prescriber Service Providing Erectile Dysfunction Medications 3Health News:PathNet Esoteric Laboratory Institute Main Laboratory Receives Accreditation From College of American Pathologists 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: